Table 3:

Summary of Liver Function Tests by Treatment Arm - Safety Population

		Solithromycin N=70		Comparator N=24
Outcome		Screening n/N (%)	Follow-Up n/N (%)	Screening n/N (%)	Follow-Up n/N (%)
ALT	> ULN	3 (4.6%)	11 (16.4%)	1 (4.3%)	3 (13.6%)
	> 3x ULN	0	1 (1.5%)	0	0
	> 10x ULN	0	0	0	0
	Evaluable subjects	65	67	23	22
AST	> ULN	11 (16.9%)	13 (19.4%)	3 (13.0%)	4 (18.2%)
	> 3x ULN	1 (1.5%)	1 (1.5%)	0	0
	> 10x ULN	0	0	0	0
	Evaluable subjects	65	67	23	22
ALT or AST	> ULN	12 (18.5%)	18 (26.9%)	4 (17.4%)	6 (27.3%)
	> 3x ULN	1 (1.5%)	2 (3.0%)	0	0
	> 10x ULN	0	0	0	0
	Evaluable subjects	65	67	23	22
Direct bilirubin	> ULN	1 (1.7%)	3 (4.5%)	0	1 (4.3%)
	> 3x ULN	0	0	0	0
	> 10x ULN	0	0	0	0
	Evaluable subjects	60	67	20	23

AST – aspartate aminotransferase, ALT – alanine aminotransferase, ULN – upper limits of normal